Anticancer composition containing lomustine

Abstract

The anticancer composition includes effective anticancer component selected from tyrosine kinase inhibitor and / or lomustine and slow releasing supplementary material, and may be prepared into slow released injection and slow released implant. The slow released injection includes also suspending agent and special solvent. The suspending agent has viscosity at 20-30 deg.c of 100-3000 cp and is selected from sodium carboxymethyl cellulose, etc. The slow releasing supplementary material is selected from p(LAEG-EOP), p(DAPG-EOP), p(BHET-EOP / TC), p(BHET-EOP / TC), p(BHDPT-EOP / TC), p(BHDPT-EOP / TC), p(CHDM-HOP), p(CHDM-EOP), etc. The released injection and slow released implant may be injected or set in tumor for slow releasing to maintain high medicine concentration for over 60 days to raise the treating effect and lower the systemic reaction on the medicine.

Description

(1) Technical field

[0001] The invention relates to an anticancer composition containing a tyrosine kinase inhibitor and / or lomustine, which is an anticancer sustained-release injection and a sustained-release implant, and belongs to the technical field of medicines. (2) Background technology

[0002] As a class of commonly used chemotherapeutic drugs, tyrosine kinase inhibitors have been widely used in the treatment of various malignant tumors, and the effect is relatively obvious. However, its significant toxicity greatly limits the wide application of this class of drugs.

[0003] Due to the excessive expansion and hyperplasia of solid tumors, the interstitial pressure, tissue elastic pressure, fluid pressure and interstitial viscosity are all higher than those of the surrounding normal tissues. Therefore, it is difficult for conventional chemotherapy to form an effective drug concentration in the tumor. In addition, blood vessels, connective tissue, matrix proteins, fib...